First Tracks Biotherapeutics, Inc. closed a private placement of 6,106,870 shares of common stock on October 19, 2026. In connection with the closing, the company entered into a registration rights agreement requiring it to file a resale registration statement for the investors within 30 days.
First Tracks Biotherapeutics Capital Raise of $200M
First Tracks Biotherapeutics entered into a securities purchase agreement for a $200 million private placement (PIPE) of 6,106,870 shares of common stock at $32.75 per share. The offering includes participation from several institutional investors and is intended to fund the clinical development of ANB033 and other general corporate purposes.
Value
$200M
Counterparty
Affinity Asset Advisors, LLC, First Light Asset Management, Sirenia Capital Management LP, TCGX, Trails Edge Capital Partners, Vestal Point Capital
First Tracks Biotherapeutics announced positive topline data from the first Phase 1b cohort of its drug candidate ANB033 for the treatment of Celiac Disease. The company also updated its corporate investor presentation to reflect these clinical developments.